Article

Inhibition of pyruvate dehydrogenase kinase redirects NSCLC cell metabolism and counteracts development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors

2020-05-22

Abstract excerpt

<title>Abstract</title> Background Non-small cell lung cancer (NSCLC) patients harboring oncogenic mutations in the epidermal growth factor receptor (EGFR) inevitably develop resistance to targeted therapy. Drug resistance is an example of cancer cell plasticity where cells change according to diverse microenvironmental pressure, which can be described as a way of evolution by natural selection. Metabolic rewi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 835e65af-faa8-5631-9852-1fac4abb4a51
DOI: 10.21203/rs.3.rs-29590/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of pyruvate dehydrogenase kinase redirects NSCLC cell metabolism and counteracts development of resistance to epidermal growth factor receptor tyrosine kinase inhibitorsDOI 10.21203/rs.3.rs-29590/v1Read

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cellsSemantic proximity Read

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceSemantic proximity Read

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read

Pyruvate dehydrogenase kinase expression profile is a biomarker for cancer sensitivity to dichloroacetate-mediated growth inhibitionSemantic proximity Read

Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read

Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read

Metabolism-focused CRISPR screen unveils Mitochondrial Pyruvate Carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerSemantic proximity Read

DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells.Semantic proximity Read

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second AlterationSemantic proximity Read

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancerSemantic proximity Read

NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.Semantic proximity Read

A non-canonical glucose metabolic rewiring enables resistance to cancer targeted therapySemantic proximity Read